Aims-To determine whether the polymerase chain reaction with sequence specific primers (PCR-SSP) can assign HLA-DR type more accurately than serology in a routine hospital laboratory. Methods-The 93 patients currently awaiting kidney transplants have been DR typed by serology over the past 14 years, 82% within the past five years. They have now been retyped using the PCR-SSP method described by Bein et al. Where 
Of the more than 130 HLA class II antigens currently recognised,' those encoded by alleles at the DRB1 locus seem to be of particular importance with regard to graft rejection.24
Identification of these alleles has traditionally been by serology in a complement mediated microcytotoxicity assay. With the elucidation of the DNA sequences for the HLA genes, methods have been devised for genotyping patients. First among these defined the HLA-DRB1 polymorphisms by restriction fragment length polymorphism (RFLP),5 although not all genotypes can be resolved. 6 Hybridisation of sequence specific oligonucleotide probes (SSOs) to genomic DNA can identify most known alleles, and in combination with the PCR (PCR-SSO), has become a sensitive and specific technique for genotypic analysis.7 Developments such as the reverse dot-blot8 and amplified fragment length polymorphism (AFLP)9 continue to be made.
All of these genotyping methods improve the confidence of allele assignment compared with phenotypic serology and permit more detailed identification of over The PCR-SSP was conducted using the primer sets and nested amplification described by Bein et al'O in a Perkin Elmer 480 thermocycler. DNA was extracted from 0-5 ml of EDTA or citrated blood by a rapid mini-prep adaptation of the salting-out procedure described by Olerup and Zetterquist," and redissolved by eye to a concentration of 50-100 ng/ul. The first round amplification (20 cycles) used 3,l of DNA per reaction. The products of these reactions were diluted 1 in 20 and 3 1ul used as template in each second round amplification (30 cycles). The reaction mixes (total volume 26 jl) contained 0-25 uM each of human growth hormone (HGH) primer, 05 5uM each of two allele specific primers, and 0-2 mM each dNTP in 1 x Taq reaction buffer (HT Biotechnology). After addition of the template and 30,l oil (melting point bath oil, Sigma), the tubes (thin walled PCR tubes, Anachem) were heated to 94°C for eight minutes before commencing cycling through 94°C for one minute, 65°C for 30 seconds, and 72°C for 30 seconds. Towards the end of the pre-heating period, 1 pul Taq polymerase (SuperTaq, HT Biotechnology), diluted 1 in 10 in 1 x reaction buffer from a -200C stock already diluted 1 in 10 in 10 x reaction buffer, was added. For analysis of the results, the aqueous phase was brought to the surface by centrifugation for one minute and 10ul electrophoresed on a 1% agarose (ICN)/TBE gel at 50 v/cm for about 20 minutes. Pre-and post-amplification samples were handled using separate, dedicated sets of pipettes to avoid risks of crosscontamination.
For all patients where results by the two methods were not in agreement, PCR-SSP was repeated, once by the same method and once using the Olerup primers. The latter method was performed using a primer kit supplied through The British Society for Histocompatibility and Immunogenetics (BSHI) exactly according to their protocol for 13 ,ul reactions, except that cycling times (35 seconds at 94°C, 70 seconds at 63°C) were adapted for our first generation PCR machine.
Results
Comparison of results obtained by serology and PCR-SSP for the 93 patients revealed 13 (14%) discrepancies (table 1) .
Two of these were initial mistyping by PCR, but the problems causing these have subsequently been resolved. In case 1 PCR-SSP suggested that the patient was homozygous DR4, while serology defined the additional presence of a DR6 allele. The apparent discrepancy between the results encouraged us to develop further the Bein PCR primer sets,'7 so that we could detect the normally "undetectable" alleles DRB1*1305, *1404, and *1410. The patient was found to carry the DRB1*1404 allele. The second mistyping by PCR (case 2) would have replaced a serological "blank" with a DR8 allele. We have subsequently noted that DRw1 7 patients frequently cause some degree of positive reaction with the DR8 primer set. PCR-SSP with the Olerup primers also suggested that this was a false positive.
Three patients (cases 3-5) were shown to carry the DRB1*0103 allele by PCR but not by serology. These patients were all typed before the provision of DRB 1 *0103 antiserum on the typing plates used.
Five patients (cases 6-10) were recorded as homozygous by serology but were shown to be heterozygous by PCR-SSP. The discrepancies can be explained as follows. Because it was impossible to define the presence of DR12 in the presence of DRil by serology, case 6 was recorded as homozygous. Cases 7 and 9 were first typed in 1984 and 1990, respectively, before assignment of DR9 was reliable using serology. The DR6 allele was missed by serology in case 8 because there Where x is second allele on which the two methods agreed. Where y and z were second alleles on which the two methods did not agree.
was only a weak reaction to the antisera, possibly because of poor B cell purity (typing was done before the use of Dynabeads). The failure to detect DR2 in case 10 is attributed to the date-1983-of the original serological typing.
The final three discrepancies (cases 1 1-13) were due to the wrong assignment of alleles by serology. Of these, case 11 had been originally typed 14 years ago and never rechecked. On repeating the serology this year, in response to PCR findings, results were at variance with the patient's reported DR type but in concordance with PCR findings. Case (table 2) . The other two cases were due to the fact that although the splits can now be determined by serology, the antisera to do this were not commonly available when the patients presented in 1987 (DR5 patient) and 1988 (DR2 patient).
For 14% of patients at least some second round PCR reactions had to be repeated. More than 50% of these were because of failed control reactions in one or more tubes for patients who were actually homozygous. It is not possible for the serological typings to say how many fresh blood samples, extra B cell separations, or repeat typing reactions were necessary as no records had been kept.
Discussion
Our study has shown that within a routine hospital tissue typing laboratory, PCR-SSP is more accurate than serology for DRB1 typing. Because of the design of the study, the 11 8% serology failure rate perhaps has limited value as an actual measure of the improvement that is possible. This laboratory is currently above the United Kingdom average for the accuracy of its serological tissue typing as measured by the National External Quality Assurance Scheme, so some laboratories might expect to see a greater improvement in their accuracy if they matched or surpassed our PCR-SSP performance.
We might equally be overestimating the advantage to be gained by PCR-SSP. Although there have been major improvements in B cell separation and antisera specificity since many of the serotypings were performed, several of the difficulties which were encountered still remain. In our laboratory, although the presence of a second allele has been suspected, DRB 1*0103 has not been successfully assigned by serology. Both DRB1*1303 and *1305 have been misassigned as DR5 by serology, probably because of their unusual DQwl association. The differentiation of DR4 and DR9 is still difficult in our experience, as can be the defining of a DR6 split.
Almost 40% of the patients had originally been typed before the introduction of Dynabeads to improve B cell separation. None had been retyped until this study. Serological retyping of case 11 (table 1) showed that both class I and class II antigens had originally been wrongly assigned. We suggest that as methods of tissue typing improve in accuracy, so data should be rechecked. As time on haemodialysis increases, decreased B cell viability and the concomitant problems in cell separation can make serology more difficult. 16 There is no such problem for DNA typing. We have not only easily obtained PCR quality DNA from the blood of patients receiving long term haemodialysis, but also from blood samples stored for up to the capital cost of a second generation thermocycler, on which the system was optimised, and its special reaction tubes are considerably higher than for a first generation machine. Adapting cycling parameters from one sort of PCR machine to another is not always easy. We do not obtain consistent results with the Olerup and Zetterquist primers, particularly the control set, on our machine under a variety of cycling regimens.
Both PCR-SSP methods have other drawbacks. They demand a thermocycler and submarine gel electrophoresis tank not normally available in a routine laboratory, and need two dedicated sets of micropipettes. This will not long remain merely tissue typing equipment, as more and more new PCR applications continue to be reported. Because molecular biology techniques are not yet familiar in routine hospital laboratories, the confidence necessary to use them "on call" may take time to develop. Cross-reactions (as in case 2) are not infrequent. In most cases they are relatively weak and easily discounted, but in homozygous patients or where the reaction is strong there is a danger that an allele will be wrongly assigned. Retesting suspected false positive results using a two-step PCR cycle of 94°C and 72°C for 30 seconds each, overcomes the problem. The "failure" of the PCR with one patient has been resolved by the inclusion of new primer mixes to amplify otherwise undetectable DR6 alleles.'7 While genotyping is the most accurate way of defining tissue type as currently understood, and PCR-SSP the most suitable for the everyday demands of the routine laboratory, it will only remain so if it is constantly updated to take account of newly described alleles.
